We have located links that may give you full text access.
Perioperative venous thromboembolism risk in patients undergoing hysterectomy for fibroids: a U.S. retrospective cohort study.
Journal of Obstetrics and Gynaecology Canada : JOGC 2024 April 7
OBJECTIVE: Venous thromboembolism (VTE) occurs in 0.4-0.7% of benign hysterectomies. Pelvic vascular compression secondary to fibroids may elevate VTE risk. We aimed to evaluate the incidence and timing of VTE among individuals undergoing hysterectomy for fibroids and other benign indications.
METHODS: Retrospective cohort study of patients who underwent a hysterectomy for fibroid and non-fibroid indications from January 2015 to December 2021. Main outcome measure was VTE consisting of pulmonary embolism or deep venous thrombosis diagnosed during 3 periods: i) preoperative (1 year before surgery until day before surgery), ii) early postoperative (surgery date through 6 weeks after surgery), and iii) late postoperative (6 weeks to 1 year after surgery). Demographics, comorbidities, surgical characteristics, and VTE rates were compared by indication.
RESULTS: 263 844 individuals with fibroids and 203 183 without were identified. 1.1% experienced VTE. On multivariable regression (adjusted demographic confounders and route of surgery), the presence of fibroids was associated with increased odds of preoperative (aOR 1.12, 95% CI 1.03-1.22, P = 0.011) and reduced odds of late postoperative VTE (aOR 0.81, 95% CI 0.73-0.91, P < 0.001). For individuals with fibroids, uterine weight ≥250 g and undergoing laparotomy were independently associated with preoperative (aOR 1.29, 95% CI 1.09-1.52, P = 0.003 and aOR 2.32, 95% CI 2.10-2.56, P < 0.001) and early postoperative VTE (aOR 1.32, 95% CI 1.08-1.62, P = 0.006 and aOR 1.72, 95% CI 1.50-1.96, P < 0.001).
CONCLUSION: Patients with fibroids were at increased odds of having VTE 1 year before hysterectomy. For those with fibroids, elevated uterine weight and laparotomy were associated with greater risk of preoperative and early postoperative VTEs.
METHODS: Retrospective cohort study of patients who underwent a hysterectomy for fibroid and non-fibroid indications from January 2015 to December 2021. Main outcome measure was VTE consisting of pulmonary embolism or deep venous thrombosis diagnosed during 3 periods: i) preoperative (1 year before surgery until day before surgery), ii) early postoperative (surgery date through 6 weeks after surgery), and iii) late postoperative (6 weeks to 1 year after surgery). Demographics, comorbidities, surgical characteristics, and VTE rates were compared by indication.
RESULTS: 263 844 individuals with fibroids and 203 183 without were identified. 1.1% experienced VTE. On multivariable regression (adjusted demographic confounders and route of surgery), the presence of fibroids was associated with increased odds of preoperative (aOR 1.12, 95% CI 1.03-1.22, P = 0.011) and reduced odds of late postoperative VTE (aOR 0.81, 95% CI 0.73-0.91, P < 0.001). For individuals with fibroids, uterine weight ≥250 g and undergoing laparotomy were independently associated with preoperative (aOR 1.29, 95% CI 1.09-1.52, P = 0.003 and aOR 2.32, 95% CI 2.10-2.56, P < 0.001) and early postoperative VTE (aOR 1.32, 95% CI 1.08-1.62, P = 0.006 and aOR 1.72, 95% CI 1.50-1.96, P < 0.001).
CONCLUSION: Patients with fibroids were at increased odds of having VTE 1 year before hysterectomy. For those with fibroids, elevated uterine weight and laparotomy were associated with greater risk of preoperative and early postoperative VTEs.
Full text links
Related Resources
Trending Papers
Renin-Angiotensin-Aldosterone System: From History to Practice of a Secular Topic.International Journal of Molecular Sciences 2024 April 5
Prevention and treatment of ischaemic and haemorrhagic stroke in people with diabetes mellitus: a focus on glucose control and comorbidities.Diabetologia 2024 April 17
British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease.Rheumatology 2024 April 17
Albumin: a comprehensive review and practical guideline for clinical use.European Journal of Clinical Pharmacology 2024 April 13
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app